Most of the adverse events that resulted from use of teprotumumab have been reversible, said Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica.
Most of the adverse events that resulted from use of teprotumumab have been reversible, said Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica.
Transcript
You are presenting data on the adverse events associated with teprotumumab. What did you find?
I think this is an extremely important question, especially since it concerns patient safety. Now, if you look at the original trials, the most common side effects related to headaches, fatigue, muscle cramps. And these were easily dealt with adequate hydration and rest. And on the other side of the spectrum, they also found that patients with diabetes had a propensity to increase the glucose levels once they've been treated with teprotumumab. Now, once again, with careful monitoring a lot of the serious sort of outcomes of this are circumvented and in my experience, good management of these patients means that the glucose levels, even if they do spike, are easily caught and managed on the spot.
Now, one of the other adverse events that seems to be interesting is disturbances in hearing there have been a few patients that have experienced tinnitus following treatment with teprotumumab. And at this stage, most conditions have been found to be reversible. There have been a few instances where patients have had more long-term hearing disturbance, but it remains unclear if they had hearing disturbances to begin with before treatment. So, to look into this in more detail, we've designed some studies that will prospectively look at hearing disturbance to try and see the full incidence and prevalence in patients treated with teprotumumab.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More